Surufatinib in Chinese Patients with Locally Advanced or Metastatic Differentiated Thyroid Cancer and Medullary Thyroid Cancer: A Multicenter, Open-Label, Phase II Trial. [electronic resource]
Producer: 20211105Description: 1245-1253 p. digitalISSN:- 1557-9077
- Adult
- Aged
- Biomarkers -- blood
- Calcitonin -- blood
- Carcinoma, Neuroendocrine -- drug therapy
- Cell Differentiation
- China -- epidemiology
- Female
- Humans
- Indoles -- therapeutic use
- Iodine Radioisotopes -- therapeutic use
- Male
- Middle Aged
- Neoplasm Metastasis
- Pyrimidines -- therapeutic use
- Receptors, Vascular Endothelial Growth Factor -- metabolism
- Sulfonamides -- therapeutic use
- Thyroid Neoplasms -- drug therapy
- Time Factors
- Treatment Outcome
- Young Adult
No physical items for this record
Publication Type: Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.